Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

被引：1
|
作者：
Smit, Marie-Anne Damiette
Borghaei, Hossein
Owonikoko, Taofeek Kunle
Hummel, Horst-Dieter
Johnson, Melissa Lynne
Champiat, Stephane
Salgia, Ravi
Udagawa, Hibiki
Boyer, Michael J.
Govindan, Ramaswamy
机构：
[1] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA
[2] Fox Chase Canc Ctr, Dept Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[4] Univ Hosp Wurzburg, Translat Oncol Early Clin Trial Unit ECTU, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[5] Tennessee Oncol, Lung Canc Res, Sarah Cannon Res Inst, Nashville, TN USA
[6] Gustave Roussy, Inst Cancerol, Villejuif, France
[7] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[10] Washington Univ, Sch Med, Div Hematol, St Louis, MO USA
[11] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8577
引用
收藏
页数：1
相关论文
共 50 条
  • [11] AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
    Giffin, Michael J.
    Cooke, Keegan
    Lobenhofer, Edward K.
    Estrada, Juan
    Zhan, Jinghui
    Deegen, Petra
    Thomas, Melissa
    Murawsky, Christopher M.
    Werner, Jonathan
    Liu, Siyuan
    Lee, Fei
    Homann, Oliver
    Friedrich, Matthias
    Pearson, Joshua T.
    Raum, Tobias
    Yang, Yajing
    Caenepeel, Sean
    Stevens, Jennitte
    Beltran, Pedro J.
    Canon, Jude
    Coxon, Angela
    Bailis, Julie M.
    Hughes, Paul E.
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1526 - 1537
  • [12] PHARMACOKIN ETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
    Minocha, M.
    Thompson, C.
    Murphy, A.
    Zhou, Y.
    Parkes, A.
    Chen, X.
    Yu, B.
    Martinez, P.
    Houk, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S68 - S68
  • [13] Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
    Lobenhofer, E.
    Werner, J.
    Giffin, M.
    Engwall, M.
    Davies, R.
    Homann, O.
    Lafleur, M.
    Moffat, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S541 - S541
  • [14] Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Aparicio, Ana
    Heidenreich, Axel
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [15] THE DLL3-TARGETED HALF-LIFE EXTENDED BISPECIFIC T CELL ENGAGER (HLE BITE®) IMMUNE-ONCOLOGY THERAPY AMG 757 HAS POTENT ANTITUMOR ACTIVITY IN NEUROENDOCRINE CANCER
    Cooke, Keegan
    Estrada, Juan
    Zhan, Jinghui
    Werner, Jonathan
    Lee, Fei
    Shetty, Aditya
    Smit, Marie-Anne Damiette
    Salvati, Mark
    Bailis, Julie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A376 - A377
  • [16] Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Akamatsu, Hiroaki
    Blackhall, Fiona Helen
    Borghaei, Hossein
    Hummel, Horst-Dieter
    Johnson, Melissa Lynne
    Reck, Martin
    Zhang, Yiran
    Jandial, Danielle
    Cheng, Sunfa
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [17] Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
    Byers, Lauren Averett
    Chiappori, Alberto
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Rottey, Sylvie
    Aparicio, Ana
    Greil, Richard
    Reimers, Melissa Andrea
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [19] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
    Lordick, F.
    Buxo Orra, E.
    Cervantes, A.
    Dayyani, F.
    Rocha-Lima, C.
    Greil, R.
    van Laarhoven, H.
    Lorenzen, S.
    Kischel, R.
    Shitara, K.
    Chao, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
  • [20] Impact of patient specific factors on exposures of tarlatamab, a half-life extended DLL3-directed bispecific T-cell engager in patients with advanced small cell lung cancer
    Kong, Stephanie M.
    Minocha, Mukul
    Chen, Po-Wei
    Martinez, Pablo
    Anderson, Erik S.
    Parkes, Amanda
    Houk, Brett E.
    Lin, Chih-Wei
    CANCER RESEARCH, 2024, 84 (06)
12345